Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06613191
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-23
Brief Title:
Colonoscopy and Antiplatelet Therapy Trial
Sponsor:
None
Organization:
None
Study Overview
Official Title:
P2Y12 Inhibitor Versus Aspirin Monotherapy in Patients Undergoing Elective Screening and Surveillance Colonoscopy
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CAPTT
Brief Summary:
Patients on dual antiplatelet therapy aspirin plus a P2Y12 inhibitor clopidogrel prasugrel or ticagrelor undergoing screening or surveilance colonoscopy are at increased risk for bleeding from the procedure Patients are ussually asked to stop the P2Y12 inhibitor for the procedure Currently recommendation is that patients only on a P2Y12 inhibitor be changes to aspirin for the procedure This pilot study will evaluate if there is a large difference in bleeding between patients only taking aspirin compared with patients only taking a P2Y12 inhibitor Patinets who participate will randomly be randomly asked to stop either aspirin or the P2Y12 inhibitor 1 week before the procedure Periprocedural bleeding and bleeding after the procedure for iup to 30 days
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None